Last week, President Trump issued four executive orders aiming to reduce the price of prescription drugs in the United States. The orders came in the wake of a heated domestic debate on the current status of the American healthcare system.
Following the executive orders, Trump was scheduled to meet with pharmaceutical executives at the White House on Tuesday to discuss further solutions to rising drug costs. Big pharma’s response was nothing short of critical with the cancellation of Tuesday’s meeting.
For pharmaceutical companies, the major point of contention is the prices for which Medicare pays for prescription drugs. The executive order would force Medicare to purchase prescription drugs at the same price as other developed countries, known as the most favored nation rule. This would potentially lower the cost of prescription drugs for Americans at the cost of major drug makers.
In addition, pharmaceutical companies have requested a text version of the executive order in questions and have yet to receive one. Commenting on the matter, a source said, “We don’t even know what we’re negotiating against.” As of today, the White House declined to release the text.
